ATE413388T1 - Muskarin antagonisten - Google Patents
Muskarin antagonistenInfo
- Publication number
- ATE413388T1 ATE413388T1 AT03726436T AT03726436T ATE413388T1 AT E413388 T1 ATE413388 T1 AT E413388T1 AT 03726436 T AT03726436 T AT 03726436T AT 03726436 T AT03726436 T AT 03726436T AT E413388 T1 ATE413388 T1 AT E413388T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- formula
- compound
- muscarine antagonists
- methods
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37609302P | 2002-04-26 | 2002-04-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE413388T1 true ATE413388T1 (de) | 2008-11-15 |
Family
ID=29270760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03726436T ATE413388T1 (de) | 2002-04-26 | 2003-04-24 | Muskarin antagonisten |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6890936B2 (OSRAM) |
| EP (1) | EP1499596B1 (OSRAM) |
| JP (2) | JP4527408B2 (OSRAM) |
| CN (1) | CN1649845A (OSRAM) |
| AT (1) | ATE413388T1 (OSRAM) |
| AU (1) | AU2003228674A1 (OSRAM) |
| CA (1) | CA2484217A1 (OSRAM) |
| DE (1) | DE60324544D1 (OSRAM) |
| ES (1) | ES2315494T3 (OSRAM) |
| MX (1) | MXPA04010552A (OSRAM) |
| WO (1) | WO2003091220A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP20094705B (en) | 2003-04-24 | 2009-06-10 | Incyte Corp | Aza spiro alkane derivatives as inhibitors of metalloproteases |
| CA2579820A1 (en) * | 2004-09-20 | 2006-03-30 | Targacept, Inc. | Azaspiroalkene and azapiroalkane compounds with nicotinic cholinergic receptor activity |
| US7678363B2 (en) | 2005-08-26 | 2010-03-16 | Braincells Inc | Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs |
| AU2007299920A1 (en) * | 2006-09-19 | 2008-03-27 | Braincells, Inc. | PPAR Mediated Modulation of Neurogenesis |
| WO2008036846A2 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| US20080108574A1 (en) * | 2006-09-27 | 2008-05-08 | Braincells, Inc. | Melanocortin receptor mediated modulation of neurogenesis |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
| ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| TW200902007A (en) * | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100130477A1 (en) * | 2008-11-25 | 2010-05-27 | Astrazeneca Ab | Spirocyclobutyl Piperidine Derivatives |
| EP2475428B1 (en) | 2009-09-11 | 2015-07-01 | Probiodrug AG | Heterocylcic derivatives as inhibitors of glutaminyl cyclase |
| CN109662964A (zh) | 2010-02-09 | 2019-04-23 | 约翰斯.霍普金斯大学 | 用于改善认知功能的方法和组合物 |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| BR112012022478B1 (pt) | 2010-03-10 | 2021-09-21 | Probiodrug Ag | Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica |
| JP5945532B2 (ja) | 2010-04-21 | 2016-07-05 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| US20110281853A1 (en) | 2010-05-12 | 2011-11-17 | Rishi Arora | Compositions and methods for treating or preventing atrial fibrillation |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| DK3212637T3 (da) * | 2014-10-31 | 2021-07-12 | Indivior Uk Ltd | Dopamin-d3-receptorantagonistforbindelser |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| WO2019014427A1 (en) * | 2017-07-12 | 2019-01-17 | Vanderbilt University | ANTAGONISTS OF THE MUSCARINIC RECEPTOR OF ACETYLCHOLINE M4 |
| EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| US11325896B2 (en) | 2017-12-20 | 2022-05-10 | Vanderbilt University | Antagonists of the muscarinic acetylcholine receptor M4 |
| TWI767148B (zh) * | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04225953A (ja) * | 1990-05-07 | 1992-08-14 | Shionogi & Co Ltd | スピロ ジベンゾスベラン誘導体 |
| GB9309422D0 (en) * | 1993-05-07 | 1993-06-23 | Res Inst Medicine Chem | Chemical compounds |
| WO1999032489A1 (en) * | 1997-12-23 | 1999-07-01 | Alcon Laboratories, Inc. | Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions |
| EP1386920A4 (en) * | 2001-04-20 | 2005-09-14 | Banyu Pharma Co Ltd | benzimidazolone derivatives |
-
2003
- 2003-04-24 CN CNA038094436A patent/CN1649845A/zh active Pending
- 2003-04-24 AT AT03726436T patent/ATE413388T1/de not_active IP Right Cessation
- 2003-04-24 AU AU2003228674A patent/AU2003228674A1/en not_active Abandoned
- 2003-04-24 CA CA002484217A patent/CA2484217A1/en not_active Abandoned
- 2003-04-24 DE DE60324544T patent/DE60324544D1/de not_active Expired - Lifetime
- 2003-04-24 EP EP03726436A patent/EP1499596B1/en not_active Expired - Lifetime
- 2003-04-24 MX MXPA04010552A patent/MXPA04010552A/es unknown
- 2003-04-24 WO PCT/US2003/012694 patent/WO2003091220A1/en not_active Ceased
- 2003-04-24 ES ES03726436T patent/ES2315494T3/es not_active Expired - Lifetime
- 2003-04-24 JP JP2003587783A patent/JP4527408B2/ja not_active Expired - Fee Related
- 2003-04-28 US US10/425,376 patent/US6890936B2/en not_active Expired - Fee Related
-
2009
- 2009-12-16 JP JP2009285736A patent/JP2010059213A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003091220A1 (en) | 2003-11-06 |
| ES2315494T3 (es) | 2009-04-01 |
| DE60324544D1 (de) | 2008-12-18 |
| JP2006507220A (ja) | 2006-03-02 |
| US20040067972A1 (en) | 2004-04-08 |
| CN1649845A (zh) | 2005-08-03 |
| US6890936B2 (en) | 2005-05-10 |
| JP4527408B2 (ja) | 2010-08-18 |
| AU2003228674A1 (en) | 2003-11-10 |
| EP1499596B1 (en) | 2008-11-05 |
| HK1068136A1 (en) | 2005-04-22 |
| CA2484217A1 (en) | 2003-11-06 |
| JP2010059213A (ja) | 2010-03-18 |
| EP1499596A1 (en) | 2005-01-26 |
| MXPA04010552A (es) | 2005-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE413388T1 (de) | Muskarin antagonisten | |
| IL166271A0 (en) | Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same | |
| UA88012C2 (uk) | Похідні хіназоліндіону як інгібітори parp | |
| SE0101675D0 (sv) | Novel composition | |
| ATE433447T1 (de) | Pyrimiidinverbindungen | |
| ATE425149T1 (de) | ANILINOPYRIMIDIN DERIVATE ALS ßJNK PATHWAY INHIBITORENß, ZUSAMMENSETZUNGEN UND DAMIT VERBUNDENE BEHANDLUNGSMETHODEN | |
| BRPI0410630A (pt) | antagonista de nk1 | |
| ATE478664T1 (de) | Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren | |
| ATE453393T1 (de) | Verwendung von pyridylamiden als angiogenesehemmer | |
| DE602004008098D1 (de) | Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren | |
| DE69725825D1 (de) | 5-HT1F-Agonisten | |
| ATE250590T1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| UA93351C2 (uk) | Похідні фталазіну як інгібітори parp | |
| BR0307833A (pt) | Sìntese controlada de ziprasidona e suas composições | |
| ATE374190T1 (de) | Tetrahydrochinazolinderivate als cfr-antagonisten | |
| ATE377602T1 (de) | Morphinanderivate und ihre medizinische anwendung | |
| PL376324A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| DE60323942D1 (de) | Lipase-hemmende zusammensetzung | |
| DE602004031410D1 (de) | Inden derivate als pharmazeutika | |
| ATE359283T1 (de) | Substituierte pyrazinonverbindungen zur behandlung von entzündungen | |
| BG105710A (en) | 5ht1 antagonists for antidepressant therapy | |
| BR0212899A (pt) | Compostos orgânicos | |
| ATE335739T1 (de) | Cak inhibitoren und deren verwendungen | |
| NO20002408D0 (no) | 5-HT1F antagonister | |
| GB0223223D0 (en) | Organic compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |